Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Aldosterone antagonists in systolic heart failure

Adrienne J. Lindblad and G. Michael Allan
Canadian Family Physician February 2014, 60 (2) e104;
Adrienne J. Lindblad
Knowledge Translation and Evidence Coordinator with the Alberta College of Family Physicians.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Michael Allan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

What is the role of aldosterone antagonists in patients with chronic systolic heart failure (HF)?

Bottom line

Aldosterone antagonists reduce mortality and hospitalizations in patients with congestive HF (class II to IV). Benefits appear similar to β-blockers or angiotensin-converting enzyme inhibitors (ACEIs). Close monitoring is required for those at risk of hyperkalemia.

Evidence

  • RALES1: an RCT of 1663 patients with class III or IV HF taking ACEIs and diuretics; patients received spironolactone or placebo. Results at 24 months:

    • -A statistically significant (P < .001) reduction in mortality (35% for spironolactone vs 46% for placebo, number needed to treat [NNT] of 10) and cardiovascular hospitalization (32% for spironolactone vs 40% for placebo, NNT = 12).

    • -Adverse events included gynecomastia or breast pain (10% for spironolactone vs 1% for placebo, number needed to harm of 11) and serious hyperkalemia (potassium ≥ 6 mmol/L); not statistically different.

  • EMPHASIS-HF2: an RCT of 2737 patients with class II HF and most using ACEIs or β-blockers; patients received eplerenone or placebo. Results at 21 months:

    • -A statistically significant reduction in mortality (13% for eplerenone vs 16% for placebo, NNT = 34; P = .008) and cardiovascular hospitalization (22% for eplerenone vs 29% for placebo, NNT = 15; P < .001).

    • -Adverse events included hyperkalemia (> 5.5 mmol/L) (increase of 12% with eplerenone and 7% with placebo, number needed to harm of 22) and no difference in gynecomastia or renal failure.

  • Two meta-analyses found similar results.3,4

Context

  • With a relative risk reduction in mortality of about 25%,1,2 aldosterone antagonists compare favourably to other agents used in congestive HF: about 29% for β-blockers5 and 23% for ACEIs.6,7

  • Aldosterone antagonists are prescribed at less than half the rate of β-blockers and ACEIs and represent the greatest potential for increased systolic HF survival.8

  • Titration to target doses of ACEIs and β-blockers before adding aldosterone antagonists has been advocated9; the rates and doses of these medications were quite different in the 2 RCTs,1,2 but they had similar outcomes.

  • There is no head-to-head trial of spironolactone versus eplerenone. Spironolactone ($12 per month) could be used first; if gynecomastia or breast pain develop, switch to eplerenone ($100 per month).

Implementation

Hyperkalemia might be more common in practice than in trials.10 High-risk, complex patients were excluded, and electrolytes were monitored frequently (eg, every 4 weeks initially in RALES). Additionally, higher doses of ACEIs and β-blockers, as well as other medications that affect potassium or renal function (nonsteroidal anti-inflammatory drugs, potassium supplements, angiotensin receptor blockers), can also increase hyperkalemia.10,11 Suggestions to minimize this risk include using studied doses, frequent monitoring of electrolytes and renal function (check within first 1 to 2 weeks of starting the medication), and considering the use of a preplanned monitoring schedule with laboratory requisitions for patients.12

Notes

Tools for Practice articles in Canadian Family Physician (CFP) are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in CFP are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Pitt B,
    2. Zannad F,
    3. Remme WJ,
    4. Cody R,
    5. Castaigne A,
    6. Perez A,
    7. et al
    . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-17.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Zannad F,
    2. McMurray JJ,
    3. Krum H,
    4. van Veldhuisen DJ,
    5. Swedberg K,
    6. Shi H,
    7. et al
    . Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ezekowitz JA,
    2. McAlister FA
    . Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30(4):469-77. Epub 2008 Dec 9.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Hu LJ,
    2. Chen YQ,
    3. Deng SB,
    4. Du JL,
    5. She Q
    . Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis. Br J Clin Pharmacol 2013;75(5):1202-12.
    OpenUrlPubMed
  5. 5.↵
    1. Bonet S,
    2. Agusti A,
    3. Arnau JM,
    4. Vidal X,
    5. Diogène E,
    6. Galve E,
    7. et al
    . Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients’ characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000;160(5):621-7.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Garg R,
    2. Yusuf S
    . Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273(18):1450-6.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Flather MD,
    2. Yusuf S,
    3. Køber L,
    4. Pfeffer M,
    5. Hall A,
    6. Murray G,
    7. et al
    . Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355(9215):1575-81.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Fonarow GC,
    2. Yancy CW,
    3. Hernandez AF,
    4. Peterson ED,
    5. Spertus JA,
    6. Heidenreich PA
    . Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 2011;161(6):1024-30.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. McKelvie RS,
    2. Moe GW,
    3. Ezekowitz JA,
    4. Heckman GA,
    5. Costigan J,
    6. Ducharme A,
    7. et al
    . The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol 2013;29(2):168-81. Epub 2012 Nov 30.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Juurlink DN,
    2. Mamdani MM,
    3. Lee DS,
    4. Kopp A,
    5. Austin PC,
    6. Laupacis A,
    7. et al
    . Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351(6):543-51.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. McMurray JJ,
    2. O’Meara E
    . Treatment of heart failure with spironolactone—trial and tribulations. N Engl J Med 2004;351(6):526-8.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Dolovich L,
    2. Gavura S,
    3. Pottie K
    . Hyperkalemia associated with spironolactone therapy. Can Fam Physician 2005;51:357-60.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Family Physician: 60 (2)
Canadian Family Physician
Vol. 60, Issue 2
1 Feb 2014
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Aldosterone antagonists in systolic heart failure
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Aldosterone antagonists in systolic heart failure
Adrienne J. Lindblad, G. Michael Allan
Canadian Family Physician Feb 2014, 60 (2) e104;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Aldosterone antagonists in systolic heart failure
Adrienne J. Lindblad, G. Michael Allan
Canadian Family Physician Feb 2014, 60 (2) e104;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Les inhibiteurs du cotransporteur du sodium-glucose de type 2 pour linsuffisance cardiaque avec fraction dejection reduite
  • Sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction
  • Sacubitril-valsartan: novel therapy for heart failure
  • Higher medication doses in heart failure?
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Tools for Practice

  • Topical combination products for facial acne
  • Budesonide bests COVID-19
  • Exercise for peripheral artery disease
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2022 by The College of Family Physicians of Canada

Powered by HighWire